- Previous Close
0.0800 - Open
0.0716 - Bid 0.0700 x --
- Ask 0.0900 x --
- Day's Range
0.0716 - 0.0825 - 52 Week Range
0.0610 - 0.1970 - Volume
291,237 - Avg. Volume
1,167,059 - Market Cap (intraday)
1.517M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. It offers oesophageal Doppler Probes that is used to guide fluid and drug interventions and haemodynamic monitoring; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; DoppLink, a patient interface cable that enhances signal processing; and PressureWave, a pulse contour analysis algorithm. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting; and TrueVue monitor. Its products are used in sepsis; abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
www.deltexmedical.comRecent News: DEMG.L
View MorePerformance Overview: DEMG.L
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DEMG.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DEMG.L
View MoreValuation Measures
Market Cap
1.52M
Enterprise Value
3.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.80
Price/Book (mrq)
0.54
Enterprise Value/Revenue
1.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-72.49%
Return on Assets (ttm)
-7.77%
Return on Equity (ttm)
-57.02%
Revenue (ttm)
1.78M
Net Income Avi to Common (ttm)
-1.29M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
326k
Total Debt/Equity (mrq)
73.77%
Levered Free Cash Flow (ttm)
-1.14M